Ibubrofen in the Treatment of Patent Ductus Arteriosus in Preterm Infants: What We Know, What We Still Do Not Know

By  

Current Pharmaceutical Design, Vol. 18, Iss. 21, 2012-05 ,pp. : 3007-3018

Bentham Science Publishers

Access to resources Recommend Favorite

“What Do You Mean by Spirituality? Please Draw Me a Picture!” Complementary Faith-Based Addiction Treatment in Switzerland From the Client's Perspective

By Klingemann Harald   Schläfli Katrin   Steiner Martin  

Substance Use & Misuse, Vol. 48, Iss. 12, 2013-10 ,pp. : 1187-1202

Informa Healthcare

Access to resources Recommend Favorite

Idarucizumab: What Should We Know?

By  

Current Drug Targets, Vol. 19, Iss. 1, 2018-01 ,pp. : 81-88

Bentham Science Publishers

Access to resources Recommend Favorite

Penetration of Antibacterials into Bone: What Do We Really Need to Know for Optimal Prophylaxis and Treatment of Bone and Joint Infections?

By Pea Federico  

Clinical Pharmacokinetics, Vol. 48, Iss. 2, 2009-01 ,pp. : 125-127

Adis International

Access to resources Recommend Favorite

Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know

By Jones Drew R   Miller Grover P  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 7, 2011-07 ,pp. : 857-874

Informa Healthcare

Access to resources Recommend Favorite